JACC:基于心电图的肥厚型心肌病人工智能检测算法

2020-02-24 不详 MedSci原创

肥厚型心肌病(HCM)是一种不常见但重要的心源性猝死原因。本研究的目的旨在开发一种基于12导联心电图(ECG)的HCM人工智能检测方法。本研究利用12导联心电图对2448例确诊为HCM的患者和51153例年龄性别匹配的非HCM对照者进行卷积神经网络(CNN)的检测。随后,CNN会在612名HCM患者和12788名对照进行验证。HCM组患者的平均年龄为54.8 ± 15.9岁,对照组平均年龄为57.

肥厚型心肌病(HCM)是一种不常见但重要的心源性猝死原因。本研究的目的旨在开发一种基于12导联心电图(ECG)的HCM人工智能检测方法。

本研究利用12导联心电图对2448例确诊为HCM的患者和51153例年龄性别匹配的非HCM对照者进行卷积神经网络(CNN)的检测。随后,CNN会在612名HCM患者和12788名对照进行验证。HCM组患者的平均年龄为54.8 ± 15.9岁,对照组平均年龄为57.5 ± 15.5岁。验证数据集中的CNN曲线下面积(AUC)为0.95(95%[CI]:0.94-0.97),HCM的最佳概率阈值为11%。当将该阈值应用于后续的验证中,CNN的AUC为0.96 (95% CI: 0.95-0.96),敏感度和特异度分别为87%和90%。该模型对年轻患者的诊断率会更高(敏感度和特异度分别为95%和92%)。

研究结果显示,基于ECG的HCM人工智能检测算法具有较高的诊断性能,尤其是对年轻患者。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854665, encodeId=a20118546650a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Aug 09 07:23:00 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326496, encodeId=4eb7132649697, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Feb 26 05:23:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622435, encodeId=1f29162243563, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 26 05:23:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379628, encodeId=7ada3e96288b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Feb 24 21:03:24 CST 2020, time=2020-02-24, status=1, ipAttribution=)]
    2020-08-09 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854665, encodeId=a20118546650a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Aug 09 07:23:00 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326496, encodeId=4eb7132649697, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Feb 26 05:23:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622435, encodeId=1f29162243563, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 26 05:23:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379628, encodeId=7ada3e96288b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Feb 24 21:03:24 CST 2020, time=2020-02-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854665, encodeId=a20118546650a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Aug 09 07:23:00 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326496, encodeId=4eb7132649697, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Feb 26 05:23:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622435, encodeId=1f29162243563, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 26 05:23:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379628, encodeId=7ada3e96288b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Feb 24 21:03:24 CST 2020, time=2020-02-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854665, encodeId=a20118546650a, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Aug 09 07:23:00 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326496, encodeId=4eb7132649697, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Feb 26 05:23:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622435, encodeId=1f29162243563, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 26 05:23:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379628, encodeId=7ada3e96288b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Feb 24 21:03:24 CST 2020, time=2020-02-24, status=1, ipAttribution=)]
    2020-02-24 qingfengqishi5

    学习了,学习了

    0

相关资讯

JACC:冠脉介入术后晚期支架相关不良事件的研究

大部分的经皮冠脉介入治疗(PCI)术后支架相关主要不良心血管事件(MACE)是发生在术后1年内,晚期(>1年)的支架相关不良事件尚未阐明。本研究的目的旨在评估晚期支架相关MACE。本研究纳入分析了25032名接受PCI治疗的患者,其中有3718名接受的是裸金属支架(BMS),7934名接受的是一代药物洗脱支架(DES1),13380名接受的是二代药物洗脱支架(DES2)。MACE在术后1年内的发生

JACC:长期暴露于PM2.5会增加心血管疾病发生风险

长期接触细颗粒物(PM2.5)对心血管疾病(CVDs)的影响,在中国和其他同样高水平的国家中尚未完全阐明。本研究的目的旨在评估中国PM2.5对CVD发生的长期影响。本研究纳入分析了China-PAR临床研究中的116972名无基础心血管疾病的参与者,随访时间为15年。China-PAR临床研究中的PM2.5监测点每年的平均PM2.5浓度为25.5-114.0 μg/m3,PM2.5暴露每增加10u

JACC:外周动脉疾病患者预后的存在性别差异

外周动脉疾病(PAD)会增加主要不良心血管事件(MACE)的风险。本研究的目的旨在评估PAD患者的MACE风险的性别差异。本EUCLID临床研究纳入分析了13885名PAD患者(女性占28%),不同性别患者之间的PAD严重程度和药物治疗无明显差异。女性患者的年龄更大(p < 0.001),且糖尿病、高血压高脂血症和慢性肾脏疾病的概率更大。经过平均30个月时间的随访,女性患者的MACE风险更低

Circulation:既往十年,女性在心血管试验中的参与情况

心血管疾病是世界范围内女性的首要死因,但女性在心血管试验中的代表性历来不足。本研究系统的评估了2010年-2017年期间已完成的心血管试验中女性的参与情况,并记录了包括疾病类型、资助类型、国家、试验规模、干预类型和试验参与者的人口统计特征。研究人员计算了每个试验的男女比例,并通过将女性在试验参与者中的百分比除以女性在疾病人口中的百分比,明确女性参与的预估值(参与比率在0.8-1.2表明患病率相当和

盘点:JACC2月第三期研究一览

1. evolocumab治疗家族性高胆固醇血症的远期预后研究DOI: 10.1016/j.jacc.2019.12.020http://www.onlinejacc.org/content/75/6/565对不能达到低密度脂蛋白胆固醇(LDL-C)目标的家族性高胆固醇血症(FH)患者,前蛋白转化酶-枯草杆菌蛋白酶9抑制剂治疗是一种治疗选择。本研究的目的旨在评估evolocumab对纯合F

JACC:癌症药物临床试验中的心血管事件研究

心血管疾病(CVD)逐渐成为抗癌治疗效果的限制因素,本研究的目的旨在评估癌症药物试验中心血管疾病事件报告的发生率、一致性和特征。本研究纳入分析了1998-2018年所有美国FDA批准过的癌症药物临床试验,主要终点事件是主要不良心血管事件(MACE),次要终点事件是任何CVD的报道。最终共纳入189个临床试验的123个药物,参与人数有97365名(平均年龄58.5 ± 5岁,女性占46%),经过平均